about
Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopyExploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastographyTumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastographySimultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data.Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study.Effective blood signal suppression using double inversion-recovery and slice reordering for multislice fast spin-echo MRI and its application in simultaneous proton density and T2 weighted imaging.Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development.Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.False-negative MRI biomarkers of tumour response to targeted cancer therapeuticsGadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-MRI in small animals.Dependence of DCE-MRI biomarker values on analysis algorithm.Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.T1 Relaxation Time in Lungs of Asymptomatic SmokersOxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer ModelsUse of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumoursMRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion castingOvercoming the low relaxivity of gadofosveset at high field with spin locking.Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibitionQualification of imaging biomarkers for oncology drug development.Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome.COPD Patients Have Short Lung Magnetic Resonance T1 Relaxation Time.Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.Exploring ΔR(2) * and ΔR(1) as imaging biomarkers of tumor oxygenation.Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-fluorodeoxyglucose PET-CT and MRI: a pilot study.Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor modelMagnetic resonance transverse relaxation time T2 of knee cartilage in osteoarthritis at 3-T: a cross-sectional multicentre, multivendor reproducibility study.Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science.Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using noninvasive magnetic resonance imaging.Comparison of dynamic contrast-enhanced MRI and dynamic contrast-enhanced CT biomarkers in bladder cancer.No loss of cartilage volume over three years in patients with knee osteoarthritis as assessed by magnetic resonance imaging.Magnetic resonance imaging measurement of knee cartilage volume in a multicentre study.Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma.Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: application to dynamic contrast-enhanced MRI biomarkers.Ultrasound assessment of tendons in asymptomatic volunteers: a study of reproducibility.
P50
Q28728870-5637100C-3E96-4AA8-B988-5E71AF7D883BQ30401747-7BCA7058-DD14-45D9-BC35-8ECD3FCB5E69Q30764503-600F70B1-6A6B-418C-8522-D84D19036C95Q30770588-76A2D180-3168-4EEF-BEDE-FC62554A2922Q30959022-C1784934-EA8A-445C-B9F8-0C67422C7E33Q30972292-ACDC1595-9183-4057-9D75-AA0EEF193585Q33678290-51CF4999-1E26-4CCD-B7E3-DA639944B362Q34121080-92E2CA3D-6BD9-45A6-B27A-5C142BD46E9AQ34145257-13A12AB1-1BFB-445E-AA00-F94AEBB07B9BQ34273077-2B6FFFEB-2510-499C-89AA-1D74EF742F0AQ34974971-450CAE49-9B41-4E67-8DF4-D740D6D512D4Q35231566-4040A9C1-FEA1-44E2-A56F-2C8DCC71DF4FQ35711964-A8B5E8AD-AB72-48F0-9765-A00E1B9A61A6Q35905017-1FC39CA9-8B70-48A9-AA72-D88D6177E848Q35950823-9C7FD762-3B5F-4990-A1EA-197C52C5B31DQ36591139-FCF2BCF7-A6E0-40AB-8F3F-FE54909974CBQ36671549-8C38C04C-3186-4507-AFAB-7A88A894F2AFQ36852895-14E74028-07A7-4C07-B476-20AAE8C26D7BQ36882304-FDD553A1-3BAA-4446-BBBC-D14E805E55F2Q37182194-926DEB7E-0A02-4CF9-BFFB-EA815BC70D38Q37279800-126E4F04-C52C-4667-96C3-9EBE00443B88Q37973917-217847EA-3FA4-409A-B895-61D81E7212EDQ38007857-CAA2D172-4B0B-4A94-A10D-5C88F95F50E9Q38271116-6D2ED977-24F4-4F24-BAE3-9D5E4EA6AE2AQ38613003-C7280E89-6AA2-4A97-B470-D43F6336D416Q39135499-EC48DE52-F2CE-4709-920D-1B2C3EC4B10DQ39215493-900CACC7-FC0F-4ADD-9E25-811191E6E6FDQ41447353-5B32ED0F-B9BD-4CA4-9B81-E6F0B459BC1CQ41558054-AD51F50D-5FAC-4E58-A49B-45D9B7900EB6Q43562265-C9B292AA-BC82-431D-A601-4749222CCBF7Q43568116-305C567B-2D19-476E-A897-A2D1241FA01CQ44132033-49513A17-502A-460C-821F-91E11E2A3F36Q44523834-084070AB-F788-4E3C-B718-A072367FF0CEQ45096491-D3E72364-60CF-4BC5-895B-96CD893DD3F3Q46140795-B0C672D0-249D-4E70-B763-696CCF5E4FA2Q46788472-2F572627-CBA9-4A5A-B6A1-6DDB358E6583Q47684520-92B6066C-54C5-4206-A8A3-2487C28FA051Q48342333-F58C2FE3-DEA6-4043-BC05-2ED5DAFCB1ABQ50999804-69F9E2D9-CC85-4346-9405-A07ECB83F849Q52858876-DB2A47DC-6491-4DAB-93A7-381217290E0B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John C. Waterton
@ast
John C. Waterton
@en
John C. Waterton
@es
John C. Waterton
@nl
John C. Waterton
@sl
type
label
John C. Waterton
@ast
John C. Waterton
@en
John C. Waterton
@es
John C. Waterton
@nl
John C. Waterton
@sl
prefLabel
John C. Waterton
@ast
John C. Waterton
@en
John C. Waterton
@es
John C. Waterton
@nl
John C. Waterton
@sl
P1053
A-8565-2008
P106
P1153
7003731614
P21
P2798
P31
P3829
P3835
john-charles-waterton
P496
0000-0002-7734-2290